2023 CVA- DOACs in VTE and NVAF
Direct oral anticoagulants (DOACs) are used in the treatment of both venous thromboembolism (VTE) and Non-valvular atrial fibrillation (NVAF). The CDC states that VTE affects about 900,000 Americans every year, results in about 100,000 deaths per year, and costs the nation up to 10 billion dollars per year. NVAF is the primary diagonosis of over 450,000 hospitalizations and contributes to about 158,000 deaths each year.
Within Kaiser Permanente, there have been updates in 2022 for the use of DOACs for the treatment of VTE and NVAF. Updates were made to the Kaiser Permamante California Regions Treatment Algorithm for VTE and Interregional practice Recommendations for the treatment of NVAF. These updates reflect the best practices to promote safe prescribing and patient safety as well as refelct the preferred products based on formulary status within Kaiser Permanente.
The desired outcome of this presentation is to inform prescribers about the updates surrounding direct oral anticoagulants, specifically the Caliofrnia Regions Treatment Algorithm for VTE and Interregional Practice Recommendations for the treatment of Nonvalvular atrial fibrillation. The presentation will facilitate the continuous improvement of quality of care and safety in our patients, especially in patients with venous thromboembolism and non-valvular atrial fibrillation.
By the end of the activity, participants will be able to:
1. Describe the practice recommendations for the use of DOACs in patients with VTE and NVAF.
2. Recommend the appropriate pharmacological agents based on clinical factors and understand monitoring parameters.
Disclosure: The presenter & planning committee members for this activity have disclosed that they have no relevant relationships with commercial or industry organizations. The Kaiser Permanente Central Valley CME Department has reviewed their disclosure information for the planner(s) and/or committee/faculty for this program and they do not have relationships that present a relevant conflict of interest. Kaiser Permanente does not endorse any brand name products.
Kaiser Permanente Central Valley is accredited by the California Medical Association (CMA) to provide continuing medical education for physicians. The Kaiser Permanente Central Valley designates this Live Activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Attendance